Full text biomedical articles

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Jyoti Velayudhan, Yuh-feng Chen, Amanda Rohrbach, Christina Pastula, Gwen Maher, Heather Thomas, Ryan Brown, Teresa L. Born
BioDrugs. 2016; 30: 339–351. Published online 2016 Jul 15. doi: 10.1007/s40259-016-0185-2


Article   |   PubReader   |   PDF–909K   |   Cite

Adalimumab for maintenance of remission in Crohn's disease

Cochrane Database Syst Rev. 2020 May; 2020(5): CD012877. Published online 2020 May 16. doi: 10.1002/14651858.CD012877.pub2


Article   |   PubReader   |   PDF–453K   |   Cite

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Jennifer Liu, Tamer Eris, Cynthia Li, Shawn Cao, Scott Kuhns
BioDrugs. 2016; 30: 321–338. Published online 2016 Jul 26. doi: 10.1007/s40259-016-0184-3


Article   |   PubReader   |   PDF–896K   |   Cite

Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study

Eun Hye Oh, Jeongseok Kim, Namseok Ham, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Gut Liver. 2020 May 15; 14(3): 347–356. Published online 2019 Sep 19. doi: 10.5009/gnl19137


Article   |   PubReader   |   PDF–213K   |   Cite

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

Emilie Ducourau, Theo Rispens, Marine Samain, Emmanuelle Dernis, Fabienne Le Guilchard, Lucia Andras, Aleth Perdriger, Eric Lespessailles, Antoine Martin, Grégoire Cormier, Thomas Armingeat, Valérie Devauchelle-Pensec, Elisabeth Gervais, Benoit Le Goff, Annick de Vries, Eric Piver, Gilles Paintaud, Céline Desvignes, David Ternant, Hervé Watier, Philippe Goupille, Denis Mulleman
RMD Open. 2020; 6(1): e001047. Published online 2020 Jan 9. doi: 10.1136/rmdopen-2019-001047


Article   |   PubReader   |   PDF–602K   |   Cite

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Richard Markus, Helen J. McBride, Monica Ramchandani, Vincent Chow, Jennifer Liu, Dan Mytych, Gary Fanjiang
Adv Ther. 2019; 36(8): 1833–1850. Published online 2019 Jun 10. doi: 10.1007/s12325-019-00979-6


Article   |   PubReader   |   PDF–1.8M   |   Cite

Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial

H. Nakase, S. Motoya, T. Matsumoto, K. Watanabe, T. Hisamatsu, N. Yoshimura, T. Ishida, S. Kato, T. Nakagawa, M. Esaki, M. Nagahori, T. Matsui, Y. Naito, T. Kanai, Y. Suzuki, M. Nojima, M. Watanabe, T. Hibi, DIAMOND study group, Akira Andoh, Toshifumi Ashida, Katsuya Endo, Yutaka Endo, Motohiro Esaki, Hiroshi Fujita, Mikihiro Fujiya, Ken Haruma, Toshifumi Hibi, Sakiko Hiraoka, Ichiro Hirata, Tadakazu Hisamatsu, Yutaka Honda, Hideki Iijima, Bunei Iizuka, Kentaro Ikeya, Takuya Inoue, Shuji Inoue, Tetsuya Ishida, Yo Ishiguro, Shunji Ishihara, Hiroaki Ito, Ryuichi Iwakiri, Takashi Kagaya, Takanori Kanai, Hiroshi Kashida, Shingo Kato, Jun Kato, Takehiko Katsurada, Fukunori Kinjyo, Kiyonori Kobayashi, Mayumi Kodama, Reiko Kunisaki, Koichi Kurahara, Takafumi Kurokami, Lee Kyouwon, Koichiro Matsuda, Kazuhiro Matsueda, Toshiyuki Matsui, Takayuki Matsumoto, Keiichi Mitsuyama, Yuji Mizokami, Satoshi Motoya, Yuji Naito, Tomoo Nakagawa, Shiro Nakamura, Hiroshi Nakase, Masanori Nojima, Masafumi Nomura, Atsuhiro Ogawa, Kazuichi Okazaki, Kazuaki Otsuka, Hirotake Sakuraba, Masayuki Saruta, Makoto Sasaki, Takayuki Shirai, Tomoaki Suga, Kazuhito Sugimura, Toshiro Sugiyama, Yasuo Suzuki, Fuminao Takeshima, Hiroyuki Tamaki, Shinji Tanaka, Satoshi Tanida, Keiichi Tominaga, Taku Tomizawa, Kenji Watanabe, Mamoru Watanabe, Shojiro Yamamoto, Masaki Yamashita, Atsushi Yoshida, Naoki Yoshimura
Aliment Pharmacol Ther. 2017 Nov; 46(9): 873–882. Published online 2017 Sep 8. doi: 10.1111/apt.14318


Article   |   PubReader   |   PDF–584K   |   Cite

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

Caitriona Ryan, Jeffrey M. Sobell, Craig L. Leonardi, Charles W. Lynde, Mahinda Karunaratne, Wendell C. Valdecantos, Barbara A. Hendrickson
Am J Clin Dermatol. 2018; 19(3): 437–447. Published online 2018 Jan 27. doi: 10.1007/s40257-017-0341-6


Article   |   PubReader   |   PDF–490K   |   Cite

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab

Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini, Meenu Wadhwa
Cytokine. 2017 Aug; 96: 16–23. doi: 10.1016/j.cyto.2017.02.015


Article   |   PubReader   |   Cite

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab

B. Gorovits, D. J. Baltrukonis, I. Bhattacharya, M. A. Birchler, D. Finco, D. Sikkema, M. S. Vincent, S. Lula, L. Marshall, T. P. Hickling
Clin Exp Immunol. 2018 Jun; 192(3): 348–365. Published online 2018 Mar 30. doi: 10.1111/cei.13112


Article   |   PubReader   |   PDF–456K   |   Cite

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy

J.‐F. Colombel, B. Jharap, W. J. Sandborn, B. Feagan, L. Peyrin‐Biroulet, S. F. Eichner, A. M. Robinson, N. M. Mostafa, Q. Zhou, R. B. Thakkar
Aliment Pharmacol Ther. 2017 Jan; 45(1): 50–62. Published online 2016 Nov 7. doi: 10.1111/apt.13838


Article   |   PubReader   |   PDF–672K   |   Cite

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

Stefan Schreiber, Katsuhiko Yamamoto, Rafael Muniz, Takafumi Iwura
Pharmacol Res Perspect. 2020 Jun; 8(3): e00604. Published online 2020 Jun 4. doi: 10.1002/prp2.604


Article   |   PubReader   |   PDF–1.9M   |   Cite

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Toshifumi Hibi, Shiro Nakamura, Andreas Lazar, Anne Martin Robinson, Martha Skup, Nael Mohamed Mostafa, Bidan Huang, Roopal Thakkar, Mamoru Watanabe
J Gastroenterol. 2017; 52(9): 1031–1040. Published online 2017 Mar 20. doi: 10.1007/s00535-017-1325-2


Article   |   PubReader   |   PDF–983K   |   Cite

A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richard Markus
Ann Rheum Dis. 2017 Mar; 76(3): 526–533. Published online 2017 Feb 17. doi: 10.1136/annrheumdis-2015-208914


Article   |   PubReader   |   PDF–1.3M   |   Cite

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell
Arthritis Res Ther. 2018; 20: 178. Published online 2018 Aug 15. doi: 10.1186/s13075-018-1676-y


Article   |   PubReader   |   PDF–957K   |   Cite

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry

Edward V Loftus, Jr., Walter Reinisch, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Joel Petersson, Roopal Thakkar, Anne M Robinson, Geert D’Haens
Inflamm Bowel Dis. 2019 Sep; 25(9): 1522–1531. Published online 2019 Feb 8. doi: 10.1093/ibd/izz008


Article   |   PubReader   |   PDF–702K   |   Cite

Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti‐adalimumab in patients with inflammatory diseases

Eva L. Kneepkens, Mieke F. Pouw, Gerrit Jan Wolbink, Tiny Schaap, Michael T. Nurmohamed, Annick de Vries, Theo Rispens, Karien Bloem
Br J Clin Pharmacol. 2017 Nov; 83(11): 2474–2484. Published online 2017 Aug 22. doi: 10.1111/bcp.13371


Article   |   PubReader   |   PDF–870K   |   Cite

Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments

Elena Krayukhina, Masanori Noda, Kentaro Ishii, Takahiro Maruno, Hirotsugu Wakabayashi, Minoru Tada, Takuo Suzuki, Akiko Ishii-Watabe, Masahiko Kato, Susumu Uchiyama
MAbs. 2017 May-Jun; 9(4): 664–679. Published online 2017 Mar 3. doi: 10.1080/19420862.2017.1297909


Article   |   PubReader   |   PDF–1.4M   |   Cite

Adalimumab for induction of remission in Crohn's disease

Mohamad Abbass, Jeremy Cepek, Claire E Parker, Tran M Nguyen, John K MacDonald, Brian G Feagan, Reena Khanna, Vipul Jairath, Cochrane IBD Group
Cochrane Database Syst Rev. 2019 Nov; 2019(11): CD012878. Published online 2019 Nov 14. doi: 10.1002/14651858.CD012878.pub2


Article   |   PubReader   |   PDF–356K   |   Cite

Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort study

Ryosuke Sakemi, Maki Miyakawa, Hiroki Tanaka, Masanao Nasuno, Satoshi Motoya, Tokuma Tanuma, Manabu Ishii, Hideyuki Yanagisawa, Masaki Yamashita, Nariaki Toita, Ryo Suzuki, Toshihisa Kobayashi, Masanori Nojima, Suketo So
Medicine (Baltimore) 2020 Nov 20; 99(47): e23344. Published online 2020 Nov 20. doi: 10.1097/MD.0000000000023344


Article   |   PubReader   |   PDF–406K   |   Cite